Table 4.

Changes at 5-year follow-up

Characteristic	Targeted therapy (N = 102)	Conventional therapy (N = 105)	Δ Targeted therapy (baseline vs. 5 years) %	Δ Conventional therapy (baseline vs. 5 years) %	P-value targeted therapy baseline vs. 5 years	P-value conventional treatment baseline vs. 5 years	P-value Δ targeted vs. conventional
Systolic blood pressure (mmHg)
Baseline	130.9 ± 15.3	128.3 ± 14.4	−1.80%	4.68%	0.062	0.008	0.003
5 years	126.4 ± 14.9	133.3 ± 16.3
Diastolic blood pressure (mmHg)
Baseline	83.4 ± 10.5	82.1 ± 9.5	−5.98%	−2.30%	<0.001	0.026	0.138
5 years	77.0 ± 9.7	79.5 ± 11.1
Body mass index (kg/m2)
Baseline	28.5 (25.8–30.9)	28.1 (25.6–30.7)	0.62%	1.37%	0.395	0.023	0.292
5 years	28.4 (25.6–31.4)	28.4 (25.8–31.4)
NT-ProBNP (ng/L)
Baseline	1071 (687–1537)	987 (683–1548)	−34.94%	−23.99%	<0.001	<0.001	0.428
5 years	475 (118–828)	512 (135–1038)
Total cholesterol (mmol/L)
Baseline	5.0 (4.2–5.7)	4.0 (4.1–5.8)	−14.56%	−3.13%	<0.001	0.015	0.003
5 years	4.0 (3.5–4.8)	4.7 (3.9–5.4)
LDL cholesterol (mmol/L)
Baseline	3.0 (2.4–3.8)	2.9 (2.5–3.8)	−16.50%	−5.59%	<0.001	0.002	0.017
5 years	2.1 (1.7–2.7)	2.7 (2.1–3.6)
Left atrial volume indexed (mL/m2)
Baseline	39 (31–48)	38 (31–48)	9.50%	11.91%	0.925	0.218	0.542
5 years	39 (32–48)	40 (30–49)
LVEF
Baseline	54 (43–59)	52 (43–60)	11.25%	13.12%	0.001	<0.001	0.831
5 years	55 (50–60)	55 (51–60)
Urine sodium (mmol/24 h)
Baseline	161 (118–210)	166 (122–217)	−10.80%	−11.64%	0.118	0.125	0.691
5 years	162 (102–196)	159 (125–193)
Exercise test (W)
Baseline	137 (108 –165)	134 (100–160)	0.26%	−3.82%	0.128	0.005	0.851
5 years	139 (99–173)	126 (90–162)

Data are presented as mean (SD), number of patients (%), or median (IQR). Delta represents mean change at 5-year follow-up in percentages.

LDL, low-density lipoprotein; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-brain natriuretic peptide.